


IN THE CLAIMS

The status of each claim is listed below.

Claims 1-81: Canceled.

82. (Currently Amended) A compound represented by formula (I):



wherein



X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or -N(R²)₂;

R¹ is hydrogen or lower alkyl;


each R² is, independently, -R⁷, -(CH₂)_m-OR⁸, -(CH₂)_m-NR⁷R¹⁰, -(CH₂)_n(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂CH₂O)_m-R⁸, -(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰, -(CH₂)_n-C(=O)NR⁷R¹⁰, -(CH₂)_n-Z_g-R⁷, -(CH₂)_m-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂)_n-CO₂R⁷, or

R³ and R⁴ are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R³ and R⁴ is a group represented by formula (A):




wherein

each R^L is, independently, $-\text{R}^7$, $-(\text{CH}_2)_n\text{-OR}^8$, $-\text{O}-(\text{CH}_2)_m\text{-OR}^8$, $-(\text{CH}_2)_n\text{-NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2)_m\text{-NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$, $-\text{O}-(\text{CH}_2)_m(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$, $-(\text{CH}_2\text{CH}_2\text{O})_m\text{-R}^8$, $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{-R}^8$, $-(\text{CH}_2\text{CH}_2\text{O})_m\text{-CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m\text{-CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n\text{-C(=O)NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2)_m\text{-C(=O)NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n\text{-Z}_g\text{-R}^7$, $-\text{O}-(\text{CH}_2)_m\text{-Z}_g\text{-R}^7$, $-(\text{CH}_2)_n\text{-NR}^{10}\text{-CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$, $-\text{O}-(\text{CH}_2)_m\text{-NR}^{10}\text{-CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n\text{-CH}_2\text{OR}^8$, $-(\text{CH}_2)_n\text{-CO}_2\text{R}^7$, $-\text{O}-(\text{CH}_2)_m\text{-CO}_2\text{R}^7$, $-\text{OSO}_3\text{H}$, $-\text{O}\text{-glucuronide}$, $-\text{O}\text{-glucose}$, or




each x is, independently, O , NR^7 , C=O , CHOH , C=N-R^6 , or represents a single bond;

each o is, independently, an integer from 0 to 10;
 each p is, independently, an integer from 0 to 10;
 with the proviso that (a) the sum of o and p in each contiguous chain is
 from 1 to 10 when x is O, NR⁷, C=O, or C=N-R⁶ or (b) that the sum of o and p
 in each contiguous chain is from 4 to 10 when x represents a single bond;
 each R⁶ is, independently, -R⁷, -OH, -OR¹¹, -N(R⁷)₂, -(CH₂)_m-OR⁸,
 -O-(CH₂)_m-OR⁸, -(CH₂)_n-NR⁷R¹⁰, -O-(CH₂)_m-NR⁷R¹⁰,
 -(CH₂)_n(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -O-(CH₂)_m(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,
 -(CH₂CH₂O)_m-R⁸, -O-(CH₂CH₂O)_m-R⁸, -(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰,
 -O-(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰, -(CH₂)_n-C(=O)NR⁷R¹⁰,
 -O-(CH₂)_m-C(=O)NR⁷R¹⁰, -(CH₂)_n-(Z)_g-R⁷, -O-(CH₂)_m-(Z)_g-R⁷,
 -(CH₂)_n-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,
 -O-(CH₂)_m-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸,
 -(CH₂)_n-CO₂R⁷, -O-(CH₂)_m-CO₂R⁷, -OSO₃H, -O-glucuronide, -O-glucose,



wherein when two R⁶ are -OR¹¹ and are located adjacent to each other on a phenyl
 ring, the alkyl moieties of the two R⁶ may be bonded together to form a methylenedioxy
 group;

each R⁷ is, independently, hydrogen or lower alkyl;
 each R⁸ is, independently, hydrogen, lower alkyl, -C(=O)-R¹¹, glucuronide, 2-
 tetrahydropyranyl, or



each R⁹ is, independently, -CO₂R⁷, -CON(R⁷)₂, -SO₂CH₃, or -C(=O)R⁷;

each R¹⁰ is, independently, -H, -SO₂CH₃, -CO₂R⁷, -C(=O)NR⁷R⁹,

-C(=O)R⁷, or -CH₂-(CHOH)_n-CH₂OH;

each Z is, independently, CHO_H, C(=O), CHNR⁷R¹⁰, C=NR¹⁰, or NR¹⁰;

each R¹¹ is, independently, lower alkyl;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each Q is, independently, ~~C-R⁵~~; C-R⁶; or a nitrogen atom, wherein two Q in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

83. (Previously Presented) The compound of Claim 82, wherein Y is -NH₂.

84. (Previously Presented) The compound of Claim 83, wherein R² is hydrogen.

85. (Previously Presented) The compound of Claim 84, wherein R¹ is hydrogen.

86. (Previously Presented) The compound of Claim 85, wherein X is chlorine.

87. (Previously Presented) The compound of Claim 86, wherein R³ is hydrogen.

88. (Previously Presented) The compound of Claim 87, wherein each R^L is hydrogen.

89. (Previously Presented) The compound of Claim 88, wherein o is 4.

90. (Previously Presented) The compound of Claim 89, wherein p is 0.

91. (Previously Presented) The compound of Claim 90, wherein x represents a single bond.

92. (Previously Presented) The compound of Claim 91, wherein each R⁶ is hydrogen.

93. (Previously Presented) The compound of Claim 82, wherein

X is halogen;

Y is -N(R⁷)₂;

R¹ is hydrogen or C₁-C₃ alkyl; and

R² is -R⁷, -(CH₂)_m-OR⁷, or -(CH₂)_n-CO₂R⁷;

R³ is a group represented by formula (A); and

R⁴ is hydrogen, a group represented by formula (A), or lower alkyl.

94. (Previously Presented) The compound of Claim 93, wherein

X is chloro or bromo;

Y is -N(R⁷)₂;

R^2 is hydrogen or C_1 - C_3 alkyl;
at most three R^6 are other than hydrogen as defined above; and
at most three R^L are other than hydrogen as defined above.

95. (Previously Presented) The compound of Claim 94, wherein Y is $-NH_2$.

96. (Previously Presented) The compound of Claim 95, wherein
 R^4 is hydrogen;
at most one R^L is other than hydrogen as defined above; and
at most two R^6 are other than hydrogen as defined above.

97. (Previously Presented) The compound of Claim 96, wherein x is O, NR^7 , $C=O$,
 $CHOH$, or $C=N-R^6$.

98. (Previously Presented) The compound of Claim 97, wherein x represents a single bond.

99. (Previously Presented) The compound of Claim 82, wherein x is O, NR^7 , $C=O$,
 $CHOH$, or $C=N-R^6$.

100. (Previously Presented) The compound of Claim 82, wherein x represents a single bond.

101. (Previously Presented) The compound of Claim 82, wherein each R^6 is hydrogen.

102. (Previously Presented) The compound of Claim 82, wherein at most two R⁶ are other than hydrogen as defined in Claim 82.

103. (Previously Presented) The compound of Claim 82, wherein one R⁶ is other than hydrogen as defined in Claim 82.

104. (Previously Presented) The compound of Claim 82, wherein one R⁶ is -OH.

105. (Previously Presented) The compound of Claim 82, wherein each R^L is hydrogen.

106. (Previously Presented) The compound of Claim 82, wherein at most two R^L are other than hydrogen as defined in Claim 82.

107. (Previously Presented) The compound of Claim 82, wherein one R^L is other than hydrogen as defined in Claim 82.

108. (Previously Presented) The compound of Claim 82, wherein x represents a single bond and the sum of o and p is 4 to 6.

109. (Previously Presented) The compound of Claim 82, which is in the form of a pharmaceutically acceptable salt.

110. (Previously Presented) The compound of Claim 82, which is in the form of a hydrochloride salt.

111. (Previously Presented) The compound of Claim 82, which is in the form of a mesylate salt.

112. (Previously Presented) A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

113. (Currently Amended) A composition, comprising:
the compound of Claim 82; and
a P2Y2 receptor agonist inhibitor.

114. (Previously Presented) A composition, comprising:
the compound of Claim 82; and
a bronchodilator.

115. (Previously Presented) A method of blocking sodium channels, comprising contacting sodium channels with an effective amount of the compound of Claim 82.